Overview

Global Vaccines Market is estimated to value over CAGR of over 6.8% during the forecast period 2022 to 2028.

The vaccines market growth can be credited to a rise in the occurrence of infectious diseases, increased financial support from the government for developing vaccines, rising emphasis on immunization, increased research and development activities in enhancing the vaccines. Conversely, the requirement of capital investments for the development of vaccines is huge which shall impede the growth of the market.

The market is fragmented into technology, type, disease indication, route of administration, patient type and region. The technology segment is categorised into inactivated and subunit vaccines, conjugate vaccines, recombinant vaccines, live attenuated vaccines, toxoid vaccines and recombinant vaccines. The conjugate vaccines held the largest vaccines market share, and this can be primarily credited to a rise in the support of the government, increase in the investments made by key players in developing conjugate vaccines. Based on the route of administration, the market is fragmented into oral administration, intramuscular and subcutaneous administration and other routes of administration. The intramuscular and subcutaneous administration is predicted to proliferate during the forecast period, and this is mainly due to its capability of providing a lower injection site reaction rate and a good immune response.

Major players included in the Vaccines Market are:

GLAXOSMITHKLINE PLC
PFIZER INC.
MERCK & CO. INC
SANOFI PASTEUR SA
CSL LIMITED
EMERGENT BIOSOLUTIONS
JOHNSON & JOHNSON
ASTRAZENECA
SERUM INSTITUTE OF INDIA PVT. LTD
BAVARIAN NORDIC
MITSUBISHI TANABE PHARMA CORP.
DAIICHI SANKYO CO. LTD.
PANACEA BIOTEC LTD.
BIOLOGICAL E LTD.
BHARAT BIOTECH

(Note: The list of the major players will be updated with the latest market scenario and trends)

Vaccines Market Segmentation:
By Technology

Conjugate Vaccines
Inactive and Subunit Vaccines
Live Attenuated Vaccines
Recombinant Vaccines
Toxoid Vaccines

By Type

Monovalent Vaccines
Multivalent Vaccines

By Disease Indication

Pneumococcal Disease
DTP
Influenza
HPV
Meningococcal Disease
Polio
Hepatitis
Rotavirus
MMR
Varicella
Herpes Zoster
Others

By Route of Administration

Intramuscular and Subcutaneous Administration
Oral Administration
Others

By Patient Type

Pediatric Patients
Adult Patients
Others

By Region

North America
Europe
Asia-Pacific
Latin America
Middle East and Africa

Regional Analysis:
The North America region is predicted to dominate the global market, and this is mainly due to a high occurrence of infectious disorders and rising investments by private and public organizations for developing vaccines and a strong presence of key market players in the region. The Asia Pacific region is expected to project the highest growth and this mainly due to rise in the disposable income leading to an increased healthcare expenditure, increase in the patient pool and growing initiatives by the government.

Competitive Landscape:

The prominent market players are GlaxoSmithKline plc., Pfizer, Inc. Merck & Co., Inc., Sanofi Pasteur SA, CSL Limited, Emergent BioSolutions, Inc., Johnson & Johnson, Serum Institute of India, AstraZeneca, Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company, Limited.

The Impact of COVID-19 on Vaccines Market:
Major pharmaceutical companies are creating strategic alliances to develop vaccines for treating COVD-19. For instance, Sanofi and GlaxoSmithKline have partnered to launch a vaccine for novel coronavirus during the second half of 2020. Sanofi will use its S-protein antigen that has produced a protein that genetically matches with the protein present on the surface of the novel coronavirus while GlaxoSmithKline will offer their pandemic adjuvant technology, an immunological agent that is added to a vaccine in order to boost its immune response and produce long-lasting immunity and more antibodies. Furthermore, Novavax, a biotechnology company based in USA, is planning to partner with Nucleus Network, an Australian company specialized in clinical trials, to initiate the testing of the NVX-CoV2373 vaccine and this will be the first vaccine for COVID-19 to be tested outside the United States. Novavax previously made efforts in developing vaccines for SARS and MERS. This experience shall assist them in developing a vaccine for COVID-19.

FutureWise Key Takeaways:

Growth prospects
SWOT analysis
Key trends
Key data-points affecting market growth

Objectives of the Study:

To provide with an exhaustive analysis on the Vaccines Market By Technology, By Type, By Disease Indication, By Route of Administration, By Patient Type and By Region.
To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
To evaluate and forecast micro-markets and the overall market
To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
The customization Mobility Care offered are free of charge with purchase of any license of the report
You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com